FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085105079> ?p ?o ?g. }

• W3085105079 abstract "Abstract Background Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in lesions from postmenopausal women with ER+ advanced breast cancer (ABC) using 16α- 18 F-fluoro-17β-estradiol positron emission tomography with low-dose computed tomography (FES-PET/CT). Methods Eligible patients were postmenopausal women with ER+, HER2− ABC; tumor progression after ≥ 6 months of 1–3 lines of endocrine treatment for ABC; and measurable or evaluable disease. Two 8-patient cohorts were enrolled: one treated with 400 mg elacestrant once daily (QD) and one treated with 200 mg elacestrant QD with dose escalation to 400 mg QD after 14 days. Elacestrant was dosed continuously until progressive disease, toxicity, or withdrawal. FES-PET/CT was performed pre-dose at baseline and 4 h post-dose on day 14. The primary endpoint was the percentage difference in FES uptake in tumor lesions (maximum 20) after 14 days of treatment compared to baseline. Overall response was investigator-assessed by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1. Results Patients ( n = 16; median age, 53.5 years) had ABC with a median 2.5 prior lines of endocrine therapy. Median reduction in tumor FES uptake from baseline to day 14 was 89.1% (Q1, Q3: 75.1%, 94.1%) and was similar in both cohorts (89.1% [Q1, Q3: 67.4%, 94.2%], 200/400 mg and 88.7% [Q1, Q3: 79.5%, 94.1%], 400 mg). Residual ER availability (> 25% persistence in FES uptake) on day 14 was observed in 3 patients receiving 200/400 mg (3/78, 37.5%) and 1 patient receiving 400 mg (1/8, 12.5%). The overall response rate (ORR) was 11.1% (1 partial response), and clinical benefit rate (CBR) was 30.8%. Median percentage change in FES uptake did not correlate with ORR or CBR. Adverse events occurring in > 20% of the patients were nausea (68.8%), fatigue (50.0%), dyspepsia (43.8%), vomiting (37.5%), and decreased appetite, dysphagia, and hot flush (31.3% each). Most events were grade 2 in severity. Conclusion Elacestrant 200 mg and 400 mg QD greatly reduced ER availability measured by FES-PET/CT. In a heavily pretreated population, elacestrant was associated with antitumor activity. Trial registration ClinicalTrials.gov, NCT02650817 . Registered on 08 January 2016" @default.
• W3085105079 created "2020-09-21" @default.
• W3085105079 creator A5007579054 @default.
• W3085105079 creator A5036534966 @default.
• W3085105079 creator A5037324565 @default.
• W3085105079 creator A5037547091 @default.
• W3085105079 creator A5038563211 @default.
• W3085105079 creator A5061495577 @default.
• W3085105079 creator A5064453966 @default.
• W3085105079 creator A5076407830 @default.
• W3085105079 creator A5078388793 @default.
• W3085105079 creator A5085041670 @default.
• W3085105079 date "2020-09-11" @default.
• W3085105079 modified "2023-10-09" @default.
• W3085105079 title "A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging" @default.
• W3085105079 cites W1585744531 @default.
• W3085105079 cites W1809083310 @default.
• W3085105079 cites W2019607817 @default.
• W3085105079 cites W2073392370 @default.
• W3085105079 cites W2087382494 @default.
• W3085105079 cites W2088783247 @default.
• W3085105079 cites W2111324624 @default.
• W3085105079 cites W2117634794 @default.
• W3085105079 cites W2137853125 @default.
• W3085105079 cites W2165946747 @default.
• W3085105079 cites W2243467818 @default.
• W3085105079 cites W2395038895 @default.
• W3085105079 cites W2404884142 @default.
• W3085105079 cites W2511064822 @default.
• W3085105079 cites W2514365970 @default.
• W3085105079 cites W2558360748 @default.
• W3085105079 cites W2564891497 @default.
• W3085105079 cites W2611953519 @default.
• W3085105079 cites W2765703634 @default.
• W3085105079 cites W2919989315 @default.
• W3085105079 cites W2944002852 @default.
• W3085105079 cites W2995918299 @default.
• W3085105079 cites W3005969763 @default.
• W3085105079 cites W4239051461 @default.
• W3085105079 doi "https://doi.org/10.1186/s13058-020-01333-3" @default.
• W3085105079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7488419" @default.
• W3085105079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32912274" @default.
• W3085105079 hasPublicationYear "2020" @default.
• W3085105079 type Work @default.
• W3085105079 sameAs 3085105079 @default.
• W3085105079 citedByCount "17" @default.
• W3085105079 countsByYear W30851050792021 @default.
• W3085105079 countsByYear W30851050792022 @default.
• W3085105079 countsByYear W30851050792023 @default.
• W3085105079 crossrefType "journal-article" @default.
• W3085105079 hasAuthorship W3085105079A5007579054 @default.
• W3085105079 hasAuthorship W3085105079A5036534966 @default.
• W3085105079 hasAuthorship W3085105079A5037324565 @default.
• W3085105079 hasAuthorship W3085105079A5037547091 @default.
• W3085105079 hasAuthorship W3085105079A5038563211 @default.
• W3085105079 hasAuthorship W3085105079A5061495577 @default.
• W3085105079 hasAuthorship W3085105079A5064453966 @default.
• W3085105079 hasAuthorship W3085105079A5076407830 @default.
• W3085105079 hasAuthorship W3085105079A5078388793 @default.
• W3085105079 hasAuthorship W3085105079A5085041670 @default.
• W3085105079 hasBestOaLocation W30851050791 @default.
• W3085105079 hasConcept C121608353 @default.
• W3085105079 hasConcept C126322002 @default.
• W3085105079 hasConcept C143998085 @default.
• W3085105079 hasConcept C203092338 @default.
• W3085105079 hasConcept C2775930923 @default.
• W3085105079 hasConcept C2776694085 @default.
• W3085105079 hasConcept C2777164284 @default.
• W3085105079 hasConcept C2778822529 @default.
• W3085105079 hasConcept C2779984678 @default.
• W3085105079 hasConcept C2780482068 @default.
• W3085105079 hasConcept C29730261 @default.
• W3085105079 hasConcept C2989005 @default.
• W3085105079 hasConcept C31760486 @default.
• W3085105079 hasConcept C46699223 @default.
• W3085105079 hasConcept C530470458 @default.
• W3085105079 hasConcept C535046627 @default.
• W3085105079 hasConcept C71315377 @default.
• W3085105079 hasConcept C71924100 @default.
• W3085105079 hasConcept C84606932 @default.
• W3085105079 hasConceptScore W3085105079C121608353 @default.
• W3085105079 hasConceptScore W3085105079C126322002 @default.
• W3085105079 hasConceptScore W3085105079C143998085 @default.
• W3085105079 hasConceptScore W3085105079C203092338 @default.
• W3085105079 hasConceptScore W3085105079C2775930923 @default.
• W3085105079 hasConceptScore W3085105079C2776694085 @default.
• W3085105079 hasConceptScore W3085105079C2777164284 @default.
• W3085105079 hasConceptScore W3085105079C2778822529 @default.
• W3085105079 hasConceptScore W3085105079C2779984678 @default.
• W3085105079 hasConceptScore W3085105079C2780482068 @default.
• W3085105079 hasConceptScore W3085105079C29730261 @default.
• W3085105079 hasConceptScore W3085105079C2989005 @default.
• W3085105079 hasConceptScore W3085105079C31760486 @default.
• W3085105079 hasConceptScore W3085105079C46699223 @default.
• W3085105079 hasConceptScore W3085105079C530470458 @default.
• W3085105079 hasConceptScore W3085105079C535046627 @default.
• W3085105079 hasConceptScore W3085105079C71315377 @default.
• W3085105079 hasConceptScore W3085105079C71924100 @default.
• W3085105079 hasConceptScore W3085105079C84606932 @default.
• W3085105079 hasIssue "1" @default.

• next